Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Regulatory News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.29
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.38 (5.352%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 7.29
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding and Additional Listing

20 Oct 2008 07:00

RNS Number : 1671G
Synairgen plc
20 October 2008
 



20 October 2008

Director dealings

Synairgen plc ("Synairgen" or the "Company") was notified on 17 October that on the same day John Ward, Finance Director, acquired 22,000 ordinary shares of 1p each in the Company ("Ordinary Shares") at 22 pence per share, equating to 0.01 per cent of the Company's issued Ordinary Share capital. Following this acquisition, Mr Ward has a beneficial interest of 44,692 Ordinary Shares, equating to 0.21 per cent of the Company's issued Ordinary Share capital. 

The Company was also notified on 17 October that on the same day Simon Shaw, non-executive chairman, exercised 700,000 of his Founder Options at nominal value. Following this exercise, Mr Shaw has a beneficial interest of 805,400 Ordinary Shares, equating to 3.71 per cent of the Company's issued share capital.

Application has been made to AIM, a market of the London Stock Exchange plc, for the admission of 700,000 Ordinary Shares (the "New Ordinary Shares"). The New Ordinary Shares are being admitted pursuant to the exercise of options under the Synairgen Chairman's 2004 New Share Option Agreement. It is expected that dealing in the New Ordinary Shares, which will rank pari passu in all respects with the existing issued share capital of the Company, will commence on 24 October 2008.

For further information:

Synairgen plc

John Ward

+44 2380 512800

Teathers Limited

Shaun Dobson/Claes Spang

+44 20 7426 9000

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSFKOKNABDDOKD
Date   Source Headline
17th Mar 20227:25 amRNSSynairgen Provides Update on ACTIV-2 Trial
14th Mar 20224:41 pmRNSSecond Price Monitoring Extn
14th Mar 20224:36 pmRNSPrice Monitoring Extension
11th Mar 20224:40 pmRNSSecond Price Monitoring Extn
11th Mar 20224:35 pmRNSPrice Monitoring Extension
8th Mar 20224:35 pmRNSHolding(s) in Company
8th Mar 20223:52 pmRNSHolding(s) in Company
4th Mar 20221:36 pmRNSHolding(s) in Company
3rd Mar 20227:00 amRNSUpdate on SNG001
24th Feb 202211:30 amRNSHolding(s) in Company
23rd Feb 202211:25 amRNSHolding(s) in Company
21st Feb 20227:00 amRNSTopline results from Phase 3 SPRINTER trial
4th Feb 20224:54 pmRNSHolding(s) in Company
28th Jan 20227:00 amRNSDirector/PDMR Shareholding
19th Jan 20222:05 pmRNSHolding(s) in Company
12th Jan 202211:53 amRNSHolding(s) in Company
7th Jan 20225:25 pmRNSHolding(s) in Company
6th Jan 202212:00 pmRNSSynairgen announces partnership with Ashfield
23rd Dec 20214:15 pmRNSHolding(s) in Company
23rd Dec 20212:19 pmRNSHolding(s) in Company
21st Dec 20215:05 pmRNSHolding(s) in Company
8th Dec 20217:00 amRNSData Presented at ESWI Influenza Conference
6th Dec 20215:30 pmRNSHolding(s) in Company
6th Dec 20217:00 amRNSSynairgen Presents SNG001 Data at ESWI
19th Nov 20212:26 pmRNSHolding(s) in Company
11th Nov 20217:00 amRNSSynairgen completes Phase III recruitment
8th Nov 202112:58 pmRNSHolding(s) in Company
26th Oct 20213:13 pmRNSHolding(s) in Company
21st Oct 20215:39 pmRNSHoldings in Company
21st Oct 20217:00 amRNSGrant of Options
20th Oct 20217:00 amRNSSNG001 progresses to Phase 3 of ACTIV-2 trial
13th Oct 20217:00 amRNSSynairgen appoints Gareth Walters, Ph.D. as CRO
5th Oct 202111:25 amRNSHolding(s) in Company
30th Sep 20217:02 amRNSNon-Executive Director Appointment
30th Sep 20217:00 amRNSInterim results
21st Sep 20217:00 amRNSSynairgen Notice of Interim Results
10th Sep 202111:30 amRNSHolding(s) in Company
12th Aug 20214:12 pmRNSExercise of Options and Total Voting Rights
6th Aug 202112:21 pmRNSHolding(s) in Company
29th Jun 20214:28 pmRNSHolding(s) in Company
18th Jun 202110:29 amRNSResult of AGM
7th Jun 20217:00 amRNSGrant of Options
25th May 20214:28 pmRNSNotice of AGM
24th May 20217:00 amRNSResults of in vitro studies
12th May 20217:00 amRNSFull Year Results
30th Apr 20217:00 amRNSHome Cohort data of SG016 Phase II trial
16th Apr 20214:37 pmRNSHolding(s) in Company
15th Apr 202111:44 amRNSHolding(s) in Company
6th Apr 20214:36 pmRNSHolding(s) in Company
15th Feb 20217:00 amRNSDosing commenced in US ACTIV-2 trial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.